Patents Assigned to Innogenetics
  • Patent number: 8686126
    Abstract: New polymorphisms in the nucleic acid sequences of the DNA polymerase/reverse transcriptase open reading frame and viral surface antigen open reading frame of the hepatitis B virus are reported. In particular, the present invention relates to the mutation YMDD?YSDD in the HBV reverse transcriptase domain and to the W196V mutation in the small HBV viral surface antigen. Said polymorphisms are affecting the detection of drug resistance mutations by genotypic methods and diagnostic kits based thereon. The present invention relates to methods and diagnostic kits for detection of a HBV virus comprising said nucleic acid polymorphisms. In particular, those methods utilizing oligonucleotides capable of hybridizing to said HBV nucleic acid polymorphisms are envisaged.
    Type: Grant
    Filed: July 19, 2012
    Date of Patent: April 1, 2014
    Assignee: Innogenetics N.V.
    Inventor: Abdurrahman Mithat Bozdayi
  • Publication number: 20130177910
    Abstract: The present invention relates to new nucleic acid sequences derived from the ITS (Internal Transcribed Spacer) region, between the 16S and 23S rRNA genes, to be used for the specific detection and/or identification of Serratia species, in particular of Serratia marcescens, Serratia ficaria and/or Serratia fonticola, in a biological sample. The present invention relates also to a method for the specific detection and/or identification of Serratia species, in particular Serratia marcescens, Serratia ficaria and/or Serratia fonticola, using said new nucleic acid sequences derived from the ITS region. It relates also to nucleic acid primers to be used for the amplification of said spacer region of Serratia species in a sample.
    Type: Application
    Filed: March 7, 2013
    Publication date: July 11, 2013
    Applicants: Roche Diagnostics GMBH, Innogenetics N.V.
    Inventors: Innogenetics N.V., Roche Diagnostics GMBH
  • Publication number: 20130171656
    Abstract: The present invention relates to new nucleic acid sequences derived from the ITS (Internal Transcribed Spacer) region, between the 16S and 23S ribosomal ribonucleic acid (rRNA) or rRNA genes, to be used for the specific detection and/or identification of Proteus species, in particular of Proteus mirabilis, Proteus vulgaris and/or Proteus penneri, in a biological sample. The present invention relates also to a method for the specific detection and/or identification of Proteus species, in particular Proteus mirabilis, Proteus vulgaris and/or Proteus penneri, using said new nucleic acid sequences derived from the ITS (Internal Transcribed Spacer) region. It relates also to nucleic acid primers to be used for the amplification of said spacer region of Proteus species in a sample.
    Type: Application
    Filed: March 6, 2013
    Publication date: July 4, 2013
    Applicants: ROCHE DIAGNOSTICS GMBH, INNOGENETICS N.V.
    Inventors: INNOGENETICS N.V., ROCHE DIAGNOSTICS GMBH
  • Patent number: 8426129
    Abstract: The present invention relates to the typing of HLA alleles. The sequence of exon 2 and exon 3 of the alleles HLA-B*3913, HLA-B*1406 and HLA-B*51new and of exon 2 of the alleles HLA-DRB1*0820, HLA-DRB1*04new and HLA-DRB4*01new are disclosed. The present invention relates to methods for typing of the alleles HLA-B*3913, HLA-B*1406 and HLA-B*51new. The present invention further provides primers and probes to be used in the methods for typing. A diagnostic kit comprising these primers and probes is also part of the present invention.
    Type: Grant
    Filed: April 14, 2008
    Date of Patent: April 23, 2013
    Assignee: Innogenetics N.V.
    Inventors: Ilse De Canck, Guy Mersch, Rudi Rossau
  • Publication number: 20130040284
    Abstract: New polymorphisms in the nucleic acid sequences of the DNA polymerase/reverse transcriptase open reading frame and viral surface antigen open reading frame of the hepatitis B virus are reported. In particular, the present invention relates to the mutation YMDD?YSDD in the HBV reverse transcriptase domain and to the W196V mutation in the small HBV viral surface antigen. Said polymorphisms are affecting the detection of drug resistance mutations by genotypic methods and diagnostic kits based thereon. The present invention relates to methods and diagnostic kits for detection of a HBV virus comprising said nucleic acid polymorphisms. In particular, those methods utilizing oligonucleotides capable of hybridizing to said HBV nucleic acid polymorphisms are envisaged.
    Type: Application
    Filed: July 19, 2012
    Publication date: February 14, 2013
    Applicant: Innogenetics N.V.
    Inventor: Abdurrahman Mithat BOZDAYI
  • Patent number: 8343493
    Abstract: A monoclonal antibody which specifically binds to the N-terminal region of A?8-x peptide, x being included from 11 to 42, and recognizes neither A?1-40 nor A?1-42 and which presents a high affinity with respect to A?8-x peptide, such as determined by an immunological complex formation between the monoclonal antibody and the peptide A?8-x.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: January 1, 2013
    Assignees: Innogenetics N.V., INSERM (Institut National de la Sante et de la Recherche Medicale), Sanofi
    Inventors: Eugeen VanMechelen, Pierre Grognet, Nicolas Sergeant, Marie Gompel, Andre Delacourte, Luc Buee, Laurent Pradier, Veronique Blanchard-Bregeon
  • Publication number: 20120308594
    Abstract: The current invention relates to a previously unrecognized clade of HCV genotypes as well as to diagnostic, prophylactic and therapeutic applications of nucleic acids, proteins, and antibodies to said protein, derived of or based on the newly characterized hepatitis C viruses.
    Type: Application
    Filed: December 9, 2011
    Publication date: December 6, 2012
    Applicant: INNOGENETICS
    Inventors: Erwin Sablon, Wim Quint, Leen-Jan Van Doorn
  • Publication number: 20120270208
    Abstract: Peptide sequences are provided which are capable of mimicking proteins encoded by HCV for use as reagents for screening of blood and blood products for prior exposure to HCV. The peptides are at least 5 amino acids long and can be used in various specific assays for the detection of antibodies to HCV, for the detection of HCV antigens, or as immunogens.
    Type: Application
    Filed: May 23, 2012
    Publication date: October 25, 2012
    Applicant: INNOGENETICS, S.A.
    Inventors: Robert J. DELEYS, Dirk Pollet, Geert Maertens, Hugo Van Heuverswjn
  • Patent number: 8278432
    Abstract: New polymorphisms in the nucleic acid sequences of the DNA polymerase/reverse transcriptase open reading frame and viral surface antigen open reading frame of the hepatitis B virus are reported. In particular, the present invention relates to the mutation YMDD?YSDD in the HBV reverse transcriptase domain and to the W196V mutation in the small HBV viral surface antigen. Said polymorphisms are affecting the detection of drug resistance mutations by genotypic methods and diagnostic kits based thereon. The present invention relates to methods and diagnostic kits for detection of a HBV virus comprising said nucleic acid polymorphisms. In particular, those methods utilizing oligonucleotides capable of hybridizing to said HBV nucleic acid polymorphisms are envisaged.
    Type: Grant
    Filed: March 29, 2002
    Date of Patent: October 2, 2012
    Assignee: Innogenetics N.V.
    Inventor: Abdurrahman Mithat Bozdayi
  • Patent number: 8163873
    Abstract: A monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau proteine. The tau protein can be obtained from a brain homogenate, itself isolated from the cerebral cortex of a patient having Alzheimer's disease.
    Type: Grant
    Filed: November 10, 2008
    Date of Patent: April 24, 2012
    Assignee: N.V. Innogenetics S.A.
    Inventors: Marc Mercken, Eva-Maria Mandelkow, Marc Vandermeeren, Eugeen Vanmechelen, Andre Vandevoorde
  • Patent number: 8124747
    Abstract: The current invention relates to a previously unrecognized clade of HCV genotypes as well as to diagnostic, prophylactic and therapeutic applications of nucleic acids, proteins, and antibodies to said protein, derived of or based on the newly characterized hepatitis C viruses.
    Type: Grant
    Filed: August 27, 2004
    Date of Patent: February 28, 2012
    Assignee: Innogenetics
    Inventors: Erwin Sablon, Wim Quint, Leen-Jan Van Doorn
  • Patent number: 8101351
    Abstract: The invention relates to a process for genotyping any HCV isolate present in a biological sample, previously identified as being HCV positive, and for classifying said isolate according to the percentage of homology with other HCV isolates, comprising the steps of: contacting said sample in which the ribonucleotides or deoxyribonucleotides have been made accessible, if need be, under suitable denaturation, with at least one probe from about 10 to about 40 nucleotides, with said probe being liable to hybridize to a region being in the domain extending from nucleotide at position ?291 to nucleotide at position ?66 of the 5? untranslated region of one of the HCV isolates represented by their cDNA sequences, with said numbering of position beginning with the first ATG codon of the open reading frame encoding the HCV polyprotein, or with said probe being complementary to the above-defined probes, detecting the complexes possibly formed between said probe and the nucleotide sequence of the HCV isolate to be iden
    Type: Grant
    Filed: July 12, 2007
    Date of Patent: January 24, 2012
    Assignee: Innogenetics N.V.
    Inventors: Geert Maertens, Lieven Stuyver, Rudi Rossau, Hugo Van Heuverswyn
  • Publication number: 20110201098
    Abstract: A sensor is disclosed. In one embodiment, the sensor includes an insulating substrate comprising a first zone, a second zone, and an intermediate zone, where the intermediate zone comprises a portion of the second zone that overlaps the first zone. The sensor further comprises a first electrode in the first zone that comprises a first plurality of fingers of a conductive material, a second electrode in the second zone that comprises a second plurality of fingers of the conductive material that are interdigitated with the first plurality of fingers, a plurality of three-dimensional isolation structures, and a plurality of shadow zones, wherein each shadow zone is adjacent to at least one isolation structure and is substantially free of conductive material. The plurality of isolation structures may comprises hills and/or channels.
    Type: Application
    Filed: April 26, 2011
    Publication date: August 18, 2011
    Applicants: IMEC, Innogenetics
    Inventors: Wim Laureyn, Jan Suls, Paul Jacobs
  • Publication number: 20110143443
    Abstract: A monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau proteine. The tau protein can be obtained from a brain homogenate, itself isolated from the cerebral cortex of a patient having Alzheimer's disease.
    Type: Application
    Filed: November 10, 2008
    Publication date: June 16, 2011
    Applicant: N.V. Innogenetics S. A.
    Inventors: Marc Mercken, Ev-Maria Mandelkow, Marc Vandermeeren, Eugeen Vanmechelen, Andre Vandevoorde
  • Patent number: 7955883
    Abstract: Interdigitated electrode arrays are very promising devices for multi-parameter (bio)sensing, for example the label-free detection of nucleic acid hybridization for diagnostic applications. The current disclosure provides an innovative method for the affordable manufacturing of polymer-based arrays of interdigitated electrodes with ?m-dimensions. The method is based on a combination of an appropriate three-dimensional structure and a single and directional deposition of conductive material. The three-dimensional structure can be realized in a polymer material using a molding step, for which the molds are manufactured by electroplating as a reverse copy of a silicon master structure. In order to ensure sufficient electrical isolation and individual, but convenient, accessibility of the sensors in the array, the interdigitated electrode regions need to be complemented with specific features on the three-dimensional structure. Combined with the use of e.g.
    Type: Grant
    Filed: September 6, 2006
    Date of Patent: June 7, 2011
    Assignees: IMEC, Innogenetics
    Inventors: Wim Laureyn, Jan Suls, Paul Jacobs
  • Patent number: 7935490
    Abstract: The present invention relates to a solid phase immunoassay comprising on said solid phase an antigen in the presence of a reducing agent.
    Type: Grant
    Filed: August 2, 2006
    Date of Patent: May 3, 2011
    Assignee: N.V. Innogenetics
    Inventors: Geert Maertens, Joost Louwagie, Alfons Bosman, Erwin Sablon, Maan Zrein
  • Publication number: 20110059092
    Abstract: The present invention relates to a monoclonal antibody which specifically binds to the N-terminal region of A?8-x peptide, x being comprised from 11 to 42, and recognises neither A?1-40 nor A?1-42 and which presents a high affinity with respect to A?8-x peptide, such as determined by an immunological complex formation between the monoclonal antibody and the peptide A?8-x.
    Type: Application
    Filed: October 24, 2008
    Publication date: March 10, 2011
    Applicants: INNOGENETICS NV, SANOFI-AVENTIS
    Inventors: Eugeen Vanmechelen, Pierre Grognet, Nicolas Sergeant, Marie Gompel, Andre Delacourte, Luc Buee, Laurent Pradier, Veronique Blanchard-bregeon
  • Patent number: 7855052
    Abstract: The present application discloses and claims polynucleic acids relating to and/or containing HCV polynucleic acid sequences.
    Type: Grant
    Filed: November 30, 2006
    Date of Patent: December 21, 2010
    Assignee: N.V. Innogenetics S.A.
    Inventors: Geert Maertens, Lieven Stuyver
  • Patent number: 7741461
    Abstract: The current invention relates to the field of detection and identification of clinically important fungi. More particularly, the present invention relates to species specific probes originating from the Internal Transcribed Spacer (ITS) region of rDNA for the detection of fungal species such as Candida albicans, Candida parapsilosis, Candida tropicalis, Candida kefyr, Candida krusei, Candida glabrata, Candida dubliniensis, Aspergillus flavus, Aspergillus versicolor, Aspergillus nidulans, Aspergillus fumigatus, Cryptococcus neoformans and Pneumocystis carinii in clinical samples, and methods using said probes.
    Type: Grant
    Filed: October 19, 2004
    Date of Patent: June 22, 2010
    Assignees: Innogenetics N.V., Enterprise Ireland, National University of Ireland Galway
    Inventors: Terry Smith, Majella Maher, Cara Martin, Geert Jannes, Rudi Rossau, Marjo Van der Weide
  • Publication number: 20100120121
    Abstract: The invention relates to a process for genotyping any HCV isolate present in a biological sample, previously identified as being HCV positive, and for classifying said isolate according to the percentage of homology with other HCV isolates, comprising the steps of: contacting said sample in which the ribonucleotides or deoxyribonucleotides have been made accessible, if need be, under suitable denaturation, with at least one probe from about 10 to about 40 nucleotides, with said probe being liable to hybridize to a region being in the domain extending from nucleotide at position ?291 to nucleotide at position ?66 of the 5? untranslated region of one of the HCV isolates represented by their cDNA sequences, with said numbering of position beginning with the first ATG codon of the open reading frame encoding the HCV polyprotein, or with said probe being complementary to the above-defined probes, detecting the complexes possibly formed between said probe and the nucleotide sequence of the HCV isolate to be iden
    Type: Application
    Filed: July 12, 2007
    Publication date: May 13, 2010
    Applicant: Innogenetics N.V.
    Inventors: Geert Maertens, Lieven Stuyver, Rudi Rossau, Hugo Van Heuverswyn